Clinical Trial Detail

NCT ID NCT01239134
Title Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors GITR, Inc.
Indications

melanoma

Advanced Solid Tumor

Therapies

TRX518

Age Groups: adult

No variant requirements are available.